Protein kinase C-mediated modulation of FIH-1 expression by the homeodomain protein CDP/Cut/Cux.
Under normoxia, FIH-1 (factor inhibiting HIF-1) inhibits the transcriptional activity of hypoxia-inducible factor (HIF); however, under such conditions, we observed a significant level of HIF activity in renal cell carcinoma (RCC). This phenomenon could be attributed to a decrease in the level of functional FIH that has been identified in our previous work. Nonetheless, the molecular mechanism of FIH regulation in cancer, in particular RCC, was unclear until now. In this communication, we have demonstrated that in RCC, the Cut-like homeodomain protein (CDP/Cut) is involved in FIH transcriptional regulation and is controlled by a specific signaling event involving protein kinase C (PKC) zeta. Furthermore, we have defined a unique CDP/Cut binding site on the FIH promoter. With chromatin immunoprecipitation assays, we show that CDP binds to the FIH-1 promoter in vivo and that this binding is PKC zeta dependent. Moreover, we have also defined a potential phosphorylation site in CDP (serine 987) that modulates FIH expression. CDP/Cut is a transcriptional repressor that decreases FIH-1 expression and subsequently leads to a decrease in the repressor activity of FIH-1. Without this repression, HIF activity increases, allowing for the increased transcription of the genes it regulates, such as the vascular endothelial growth factor and GLUT-1 genes. Both CDP and HIF levels are increased in several cancers and are responsible for the metastatic progression of the tumors. Taken together, our results suggest for the first time a potential connection between CDP and FIH that could lead to the development of future therapeutic interventions.
Li
Jinping
J
Department of Biochemistry and Molecular Biology, Gugg 1401A, Mayo Clinic College of Medicine, 200 First Street SW, Rochester MN 55905, USA.
Wang
Enfeng
E
Dutta
Shamit
S
Lau
Julie S
JS
Jiang
Shi-wen
SW
Datta
Kaustubh
K
Mukhopadhyay
Debabrata
D
D000818:Animals; D002292:Carcinoma, Renal Cell / Q000378:metabolism; D002460:Cell Line; D005786:Gene Expression Regulation; D018398:Homeodomain Proteins / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D007680:Kidney Neoplasms / Q000378:metabolism; D006899:Mixed Function Oxygenases; D009687:Nuclear Proteins / Q000235:genetics / Q000378:metabolism*; D011401:Promoter Regions, Genetic; D011493:Protein Kinase C / Q000378:metabolism*; D034741:RNA, Small Interfering / Q000235:genetics / Q000378:metabolism; D012097:Repressor Proteins / Q000235:genetics / Q000378:metabolism*; D014157:Transcription Factors / Q000235:genetics / Q000378:metabolism*; D014158:Transcription, Genetic; D000099221:Protein Kinase C zeta
D018398:Homeodomain Proteins; D006899:Mixed Function Oxygenases; D009687:Nuclear Proteins; D011493:Protein Kinase C; D034741:RNA, Small Interfering; D012097:Repressor Proteins; D014157:Transcription Factors; D000099221:Protein Kinase C zeta; C080632:CUX1 protein, human; C439790:HIF1AN protein, human